# breast cancer - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 3922
- Completion tokens: 22615
- Reasoning tokens: 
- Total tokens: 26537
- API requests reported: 
- Elapsed seconds: 196.235
- Final benchmark system: raw; file rank 4/5; original repeat 5; model vendor: DeepSeek

---
# Multidimensional interpretation of breast cancer OS-associated transcriptomic results

All reported genes have very small FDR values (most < 1.8e-6), so the statistical evidence for association with overall survival is strong. However, the hazard ratios are modest in magnitude, mostly between 0.79 and 1.26, indicating that these are not large-effect individual biomarkers but rather coordinated biological programs shifting risk.

---

## 1. Overall biological interpretation

The prognostic transcriptome separates into two broad biological arms:

- **Risk arm:** High expression of genes involved in **cell-cycle progression, mitosis, DNA replication, RNA translation/ribosome biogenesis, ubiquitin-proteasome function, and metabolic reprogramming** is associated with shorter overall survival.
- **Protective arm:** High expression of **immune-lineage markers, extracellular matrix/stromal genes, and several epithelial/differentiation or genome-stability genes** is associated with longer overall survival.

This pattern is consistent with a model in which poor prognosis in breast cancer is driven by **tumor-cell-autonomous proliferative capacity and biosynthetic/metabolic stress**, whereas favorable prognosis is associated with **immune infiltration and a differentiated or stromal-rich tumor microenvironment**. The protective arm in particular should not be interpreted solely as tumor-suppressive tumor-cell biology: many protective genes are likely markers of non-malignant cells in the tumor microenvironment, especially dendritic cells, plasma cells, T/NK cells, and stromal fibroblasts.

The risk arm is more likely to reflect tumor-cell intrinsic programs, although proliferation signatures can also be influenced by tumor grade and immune composition. Thus, the data support a multidimensional view of prognosis in which both tumor proliferation biology and microenvironment composition contribute.

---

## 2. Core biological programs

### Program 1: Cell cycle and mitosis — risk-associated

- **Direction:** Higher expression associated with worse overall survival.
- **Supporting genes:** AURKA, TPX2, PKMYT1, KIF4A, KIF20A, RACGAP1, PRC1, CDC20, PTTG1, NUSAP1, CENPO, ZWINT, CDCA5, CKAP2L, TROAP, UBE2C, UBE2S, CCNE2, TK1, FEN1, TIMELESS, UHRF1.
- **Most fitting annotation:** Hallmark G2M Checkpoint; Reactome Cell Cycle / Mitotic Prometaphase.
- **Why these genes indicate this program:** This is a strong, multi-gene functional cluster. It includes mitotic kinases, spindle assembly factors, chromosome passenger/centralspindle components, APC/C-related ubiquitin-conjugating enzymes, and kinetochore proteins. These genes are not merely individually associated with survival; they are interdependent components of the same mitotic cell-cycle machinery.
- **Strength of evidence:** Strong. Many genes, highly significant, coherent biological pathway.
- **Major limitation:** Cell-cycle/proliferation programs are generic across aggressive cancers and may partly reflect tumor grade, proliferation rate, or immune-poor tumor composition. The data do not identify which mitotic gene is rate-limiting.

---

### Program 2: RNA translation, ribosome biogenesis, and proteostasis — risk-associated

- **Direction:** Higher expression associated with worse overall survival.
- **Supporting genes:** LARP1, YTHDF1, STIP1, UTP23, DDX41, PSMD3, UBE2S, UBE2C, USP30, FAF2.
- **Most fitting annotation:** Reactome Metabolism of RNA; GO ribosome biogenesis; KEGG Ubiquitin-mediated proteolysis.
- **Why these genes indicate this program:** LARP1 regulates translation of TOP-containing mRNAs, YTHDF1 promotes translation of m6A-modified mRNAs, UTP23 is involved in ribosome biogenesis, DDX41 is an RNA helicase, STIP1 is an Hsp70/Hsp90 co-chaperone, and PSMD3/UBE2S/FAF2/USP30 are components of ubiquitin-dependent protein turnover. Together they point to an enhanced protein-production and protein-quality-control system that supports rapid tumor growth.
- **Strength of evidence:** Moderate-to-strong. Multiple independent genes point to RNA/protein homeostasis.
- **Major limitation:** Some genes overlap with cell-cycle/proteasome biology; translation and proteostasis programs can be secondary consequences of proliferation, stress, or MYC-driven transcriptional programs.

---

### Program 3: Metabolic reprogramming and ER stress — risk-associated

- **Direction:** Higher expression associated with worse overall survival.
- **Supporting genes:** CPT1A, GPI, HACD3, ALG3, TRIB3, ATP2A2.
- **Most fitting annotation:** KEGG Glycolysis/Gluconeogenesis; KEGG Fatty acid metabolism; Hallmark Fatty Acid Metabolism.
- **Why these genes indicate this program:** CPT1A controls mitochondrial fatty-acid oxidation, GPI is a glycolytic enzyme, HACD3 participates in fatty-acid elongation, ALG3 is involved in N-glycosylation, TRIB3 is a stress-responsive pseudokinase, and ATP2A2/SERCA2 is an ER calcium pump. This combination suggests metabolic adaptation, lipid remodeling, and ER stress handling are associated with adverse prognosis.
- **Strength of evidence:** Moderate. Fewer genes than the mitotic cluster, but biologically coherent.
- **Major limitation:** Metabolic reprogramming may be a downstream feature of highly proliferative tumors rather than an independent driver. The genes are not all in a single canonical pathway.

---

### Program 4: Immune infiltration and immune signaling — protective-associated

- **Direction:** Higher expression associated with better overall survival.
- **Supporting genes:** FCER1A, JCHAIN, CD1C, CD1E, KLRB1, IL27RA, FLT3, STAT5A, STAT5B, N4BP2L1.
- **Most fitting annotation:** GO immune response; KEGG Hematopoietic cell lineage; Reactome Adaptive Immune System.
- **Why these genes indicate this program:** FCER1A, CD1C, and CD1E are dendritic-cell markers; JCHAIN is expressed by plasma/B cells; KLRB1 marks NK/T-cell subsets; FLT3 is important for dendritic-cell development; IL27RA participates in immune signaling; STAT5A/B are central to lymphocyte and mammary epithelial signaling. This pattern strongly suggests that intratumoral immune-cell content, particularly dendritic and lymphoid infiltrates, is associated with favorable survival.
- **Strength of evidence:** Strong as a composition-related signal.
- **Major limitation:** This may largely reflect the proportion of immune cells in the tumor, not necessarily a tumor-cell-intrinsic protective mechanism. It does not distinguish protective anti-tumor immunity from bystander infiltration.

---

### Program 5: Extracellular matrix, stroma, and epithelial differentiation — protective-associated

- **Direction:** Higher expression associated with better overall survival.
- **Supporting genes:** OGN, OMD, MFAP4, COL14A1, LAMA2, ADAMTS8, RELN, IGSF10, LRFN5, CLDN11, COL17A1, TP63, DST.
- **Most fitting annotation:** Reactome Extracellular Matrix Organization; KEGG ECM-receptor interaction; GO cell adhesion.
- **Why these genes indicate this program:** Many of these genes encode secreted ECM proteins, proteoglycans, or cell-adhesion molecules, while TP63, COL17A1, DST, and CLDN11 are associated with epithelial/myoepithelial differentiation and hemidesmosome/adhesion structures. Favorable survival associated with these genes may reflect a less aggressive, more differentiated tumor phenotype or a tumor microenvironment with organized stroma.
- **Strength of evidence:** Moderate-to-strong as a prognostic signal.
- **Major limitation:** These genes likely derive substantially from non-malignant stromal/myoepithelial cells. Tumor purity and tissue composition could confound the association.

---

## 3. Key genes and interaction modules

The following interaction modules are proposed, not as proven causal units, but as statistically coherent, biologically plausible modules. The gene-gene relationships are explicitly labeled: some are direct physical interactions from prior literature, while others are co-expression or pathway co-membership inferred from the input data and existing knowledge.

### Module 1: AURKA–TPX2–KIF4A–KIF20A–RACGAP1–PRC1  
- **Direction:** All risk-associated; HRs: AURKA 1.189, TPX2 1.202, KIF4A 1.199, KIF20A 1.218, RACGAP1 1.224, PRC1 1.186.
- **Potential role:** Mitotic spindle assembly, chromosome segregation, cytokinesis.
- **Gene-gene relations:** AURKA–TPX2 is a direct physical and regulatory interaction from published biochemistry; TPX2 activates AURKA. KIF4A, PRC1, RACGAP1, and KIF20A are co-members of the central-spindle/cytokinesis pathway and have known protein interactions in that context, but the current dataset only provides co-expression/pathway co-membership evidence.

### Module 2: CDC20–PTTG1–UBE2C–UBE2S–CENPO–ZWINT–CDCA5–NUSAP1  
- **Direction:** All risk-associated; HRs: CDC20 1.191, PTTG1 1.197, UBE2C 1.210, UBE2S 1.184, CENPO 1.189, ZWINT 1.191, CDCA5 1.218, NUSAP1 1.194.
- **Potential role:** Mitotic exit, APC/C-dependent degradation, kinetochore function, sister-chromatid separation.
- **Gene-gene relations:** CDC20 is a co-activator of APC/C; UBE2C and UBE2S are APC/C-associated ubiquitin-conjugating enzymes; PTTG1 is a security substrate. These are pathway co-memberships and direct interactions are known in the APC/C system from prior literature. CENPO and ZWINT are kinetochore components that connect this module to chromosome segregation.

### Module 3: LARP1–YTHDF1–STIP1–UTP23–DDX41–PSMD3–USP30–FAF2  
- **Direction:** All risk-associated; HRs: LARP1 1.261, YTHDF1 1.192, STIP1 1.237, UTP23 1.203, DDX41 1.191, PSMD3 1.183, USP30 1.222, FAF2 1.200.
- **Potential role:** mRNA translation control, ribosome biogenesis, chaperone function, ubiquitin-proteasome homeostasis.
- **Gene-gene relations:** LARP1 and YTHDF1 both regulate translation but via different mechanisms; this is pathway co-membership, not necessarily direct interaction. STIP1 is a direct co-chaperone partner of Hsp70/Hsp90 in published literature. PSMD3, UBE2S, USP30, and FAF2 are part of ubiquitin-proteasome or ubiquitin-related pathways. The dataset shows co-expression/co-association at the survival level.

### Module 4: UHRF1–TK1–FEN1–TIMELESS–CCNE2  
- **Direction:** All risk-associated; HRs: UHRF1 1.209, TK1 1.210, FEN1 1.189, TIMELESS 1.196, CCNE2 1.186.
- **Potential role:** G1/S progression, nucleotide synthesis, DNA replication-fork processing, epigenetic maintenance.
- **Gene-gene relations:** UHRF1 recruits DNMT1 to hemimethylated DNA, a regulatory interaction; FEN1 and TIMELESS are involved in replication-fork biology; CCNE2 activates CDK2 for S-phase entry; TK1 supports nucleotide pools. They are linked by pathway co-membership rather than a confirmed direct complex in this dataset.

### Module 5: GSK3B–EZR–CFL1–S100P–WNT7B  
- **Direction:** All risk-associated; HRs: GSK3B 1.227, EZR 1.227, CFL1 1.191, S100P 1.196, WNT7B 1.183.
- **Potential role:** Actin cytoskeleton remodeling, WNT signaling, cell motility, and invasion-related biology.
- **Gene-gene relations:** EZR and CFL1 both regulate actin dynamics; GSK3B and WNT7B are members of WNT signaling; S100P is a calcium-binding protein associated with metastasis. These are mainly pathway co-members or indirect/putative relationships, not direct physical interactions established by this dataset.

### Module 6: CPT1A–GPI–HACD3–ALG3–TRIB3–ATP2A2  
- **Direction:** All risk-associated; HRs: CPT1A 1.196, GPI 1.192, HACD3 1.197, ALG3 1.187, TRIB3 1.191, ATP2A2 1.238.
- **Potential role:** Fatty-acid oxidation, glycolysis, lipid elongation, N-glycosylation, ER stress response.
- **Gene-gene relations:** These are not likely to form a single physical complex. They are connected through metabolic and stress-response pathway co-membership. TRIB3 is a stress-responsive pseudokinase; ATP2A2/SERCA2 controls ER calcium homeostasis. No direct physical interaction is proposed.

### Module 7: JCHAIN–FCER1A–CD1C–CD1E–KLRB1–IL27RA–FLT3–STAT5A–STAT5B  
- **Direction:** All protective-associated; HRs: JCHAIN 0.803, FCER1A 0.793, CD1C 0.814, CD1E 0.824, KLRB1 0.822, IL27RA 0.825, FLT3 0.817, STAT5A 0.806, STAT5B 0.837.
- **Potential role:** Immune infiltration; dendritic cells, plasma cells, NK/T cells, and immune signaling.
- **Gene-gene relations:** The strong co-occurrence of these genes as protective markers most likely reflects the abundance of immune-cell populations within the tumor. This is a co-expression/composition relationship, not evidence of a direct physical interaction.

### Module 8: OGN–OMD–MFAP4–COL14A1–LAMA2–ADAMTS8–RELN–IGSF10–TP63–COL17A1–DST–CLDN11  
- **Direction:** All protective-associated; HRs: OGN 0.807, OMD 0.829, MFAP4 0.834, COL14A1 0.824, LAMA2 0.830, ADAMTS8 0.793, RELN 0.796, IGSF10 0.824, TP63 0.810, COL17A1 0.798, DST 0.807, CLDN11 0.819.
- **Potential role:** ECM organization, cell-matrix adhesion, epithelial/myoepithelial differentiation.
- **Gene-gene relations:** Many of these gene products interact within the ECM or adhesion complexes, but in this dataset they are best interpreted as co-expressed markers of stromal/differentiated tissue compartments. The dataset does not provide direct interaction evidence.

### Module 9: RPA2–RBBP8–CDKN2C–CBX7  
- **Direction:** All protective-associated; HRs: RPA2 0.832, RBBP8 0.835, CDKN2C 0.807, CBX7 0.831.
- **Potential role:** DNA damage response, replication-stress handling, CDK inhibition, cellular senescence.
- **Gene-gene relations:** RPA2 and RBBP8 are involved in DNA-damage response and resection; CDKN2C inhibits CDK4/6; CBX7 has been linked to senescence. These are connected by pathway co-membership in genome-stability/quiescence biology, not by confirmed direct interaction in this dataset.

---

## 4. Validation priorities

The following validation directions are prioritized based on the strength and coherence of the current survival-associated signals.

### Priority 1: Functional validation of the mitotic/APC/C module as a prognostic driver  
- **Classification:** Mechanistic hypothesis.  
- **Why prioritized:** The cell-cycle/mitotic cluster is the largest and most coherent risk-associated signal, with many genes encoding interdependent components.  
- **Current evidence:** Multiple genes in this module have highly significant HRs > 1.  
- **External evidence:** AURKA, UBE2C, CDC20, and related mitotic genes are widely reported as overexpressed in aggressive breast cancer, and AURKA inhibitors exist as pharmacological tools. However, drug availability alone does not prove therapeutic relevance.  
- **Next step:** CRISPR/RNAi perturbation of AURKA, TPX2, UBE2C, or CDC20 in breast cancer models, with assessment of proliferation, mitotic defects, and in vivo tumor growth.  
- **Conclusion status:** Supported hypothesis, not established causal evidence.

### Priority 2: Validate RNA translation/proteostasis module as a dependency and potential therapeutic axis  
- **Classification:** Therapeutic target hypothesis.  
- **Why prioritized:** LARP1 is the strongest individual risk-associated gene in the dataset, and the module includes multiple independent translation/proteostasis genes.  
- **Current evidence:** LARP1, YTHDF1, STIP1, UTP23, DDX41, PSMD3, USP30, and FAF2 are all risk-associated.  
- **External evidence:** Translational control and ubiquitin-proteasome activity are implicated in cancer progression; inhibitors of proteasome and chaperone pathways exist.  
- **Next step:** Genetic or pharmacological inhibition in breast cancer models, followed by polysome profiling, ribosome biogenesis assays, and proteasome activity measurements.  
- **Conclusion status:** Exploratory hypothesis.

### Priority 3: Determine whether the protective immune signal reflects true immune infiltration or merely cell-composition differences  
- **Classification:** Confounding or composition check.  
- **Why prioritized:** Many protective genes are classic lineage markers of dendritic cells, plasma cells, and NK/T cells. This could be a tissue-composition artifact rather than tumor biology.  
- **Current evidence:** FCER1A, CD1C, CD1E, JCHAIN, KLRB1, and FLT3 are all protective.  
- **External evidence:** Tumor-infiltrating lymphocytes are generally associated with favorable prognosis in several breast cancer subtypes, especially triple-negative/HER2-positive disease.  
- **Next step:** Use RNA deconvolution methods, multiplex immunohistochemistry, or single-cell RNA-seq to quantify immune-cell populations and test whether the protective signal is explained by specific cell types.  
- **Conclusion status:** Supported hypothesis for association; causal immune mechanism not established.

### Priority 4: Develop and validate the ECM/stromal protective signature as a prognostic biomarker  
- **Classification:** Biomarker.  
- **Why prioritized:** Multiple ECM/stromal genes are consistently protective, and a composite score may be clinically useful.  
- **Current evidence:** OGN, OMD, MFAP4, COL14A1, LAMA2, ADAMTS8, RELN, and IGSF10 are all protective with strong FDRs.  
- **External evidence:** Stromal and ECM-related signatures have been associated with breast cancer outcome in previous transcriptomic studies, but direction can vary by subtype and stromal composition.  
- **Next step:** Construct a parsimonious stromal/ECM risk score, validate it in independent breast cancer cohorts, and test whether it adds prognostic information beyond standard clinical variables and subtype.  
- **Conclusion status:** Exploratory hypothesis.

### Priority 5: Test whether metabolic reprogramming contributes mechanistically to poor prognosis  
- **Classification:** Mechanistic hypothesis.  
- **Why prioritized:** CPT1A, GPI, HACD3, ALG3, TRIB3, and ATP2A2 form a risk-associated metabolic/stress cluster that may identify new vulnerabilities.  
- **Current evidence:** Each gene individually shows HR > 1 with strong statistical significance.  
- **External evidence:** Fatty-acid oxidation and glycolysis support breast cancer growth and therapy resistance in preclinical models.  
- **Next step:** Metabolomics and isotope tracing in isogenic models with or without CPT1A/GPI/HACD3 perturbation; test metabolic inhibitors in combination with standard therapy.  
- **Conclusion status:** Exploratory hypothesis.

---

## 5. Evidence grounding

Interpretation of these results relies on several evidence categories, and it is important to distinguish genuinely independent evidence from overlapping sources.

- **Direct evidence from input dataset:** The hazard ratios, P values, and FDRs for all genes are direct statistical evidence of association with overall survival. However, they are not evidence of expression regulation, protein abundance, cell-type localization, or causation.
- **Pathway/ontology evidence:** Grouping genes into cell cycle, translation/proteostasis, metabolism, immune infiltration, and ECM organization is based on existing pathway annotations. This is not an independent gene-set enrichment analysis performed on the input table.
- **Protein interaction or regulatory evidence:** Some modules are supported by prior biochemical knowledge, for example AURKA–TPX2 direct activation, STIP1 binding to Hsp70/Hsp90, and CDC20/UBE2C function with APC/C. These are independent of the input data, but they are used to generate hypotheses rather than prove that these interactions explain the survival association.
- **Disease-association evidence:** Many risk genes belong to proliferation signatures already used in breast cancer prognosis; many protective genes are immune/stromal markers. This supports the biological plausibility, but much of this literature is also based on RNA expression and is therefore not fully independent.
- **Expression/tissue-specific evidence:** The protective immune and ECM modules are likely influenced by tissue composition because the genes are known markers of non-malignant immune or stromal cells. This means the survival association may be partly a “cell-count” signal rather than a tumor-cell-autonomous process.
- **Conflicting evidence:** Some signals are not easily reconciled. For example, RPA2 and RBBP8 are protective despite being involved in DNA replication/repair, while many replication genes are risk-associated. CCND2, normally a cyclin involved in cell-cycle progression, is protective in this dataset. GRHL2, an epithelial differentiation factor, is risk-associated. These apparent conflicts suggest context dependence, subtype heterogeneity, or non-tumor-cell contributions and argue against overinterpreting single genes.

---

## 6. Limitations and alternative explanations

### 1. Tissue and cell-composition effects / tumor purity
The protective immune and ECM signals may largely reflect the fraction of immune, stromal, or myoepithelial cells in the tumor sample. The risk-associated proliferation signal may also be diluted or influenced by tumor purity. This can be investigated by computational deconvolution, tumor-purity adjustment, and spatial/multiplex imaging to localize the relevant transcripts to malignant versus non-malignant cells.

### 2. Breast cancer subtype and clinical heterogeneity
Breast cancer is heterogeneous across ER, PR, HER2, grade, and stage. A pan-breast-cancer OS analysis may be confounded by subtype-specific biology. For example, immune infiltration is prognostically more important in triple-negative disease, while proliferation signatures may be stronger in luminal B–like tumors. The current data do not include subtype stratification, so the observed HRs may not apply equally to all breast cancer subtypes.

### 3. Modest hazard ratios and continuous expression scale
The HRs are statistically significant but modest. If the HR is per unit of continuous expression, the clinical magnitude may be small. This means that individual genes are unlikely to be robust single biomarkers; multi-gene programs or scores would be more appropriate.

### 4. Broad and overlapping pathway programs
Cell-cycle, RNA translation, proteostasis, and metabolic reprogramming are interconnected. UBE2C, for example, appears in both mitotic and ubiquitin-related interpretations. Such overlap can create the appearance of multiple independent programs when they may be co-regulated by shared upstream drivers such as MYC, E2F, or mTOR. Therefore, the core programs should be treated as interacting axes, not completely independent modules.

### 5. Association-versus-causation ambiguity and technical artifacts
The input data are survival association data only. They do not demonstrate that any gene drives prognosis. In addition, if the underlying expression data were generated across multiple platforms or batches, subtle batch effects could inflate or distort some associations, although the very small FDRs suggest the associations are unlikely to be purely technical.

---

## Conclusion

The current results provide strong transcriptomic evidence that poor overall survival in breast cancer is associated with coordinated activation of cell-cycle/mitotic, RNA translation/proteostasis, and metabolic programs, while favorable survival is associated with immune infiltration and ECM/stromal differentiation programs. The most robust interpretation is a combination of tumor-cell proliferation biology and tumor-microenvironment composition. These are supported hypotheses for further validation, not established causal mechanisms. The next step should be to move from gene-level hazard ratios to functional, cell-type-resolved, and subtype-aware validation.
